Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review
Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dose reductions · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in complete response compared with standard induction therapies (low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
Treatment‐related mortality · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).
1 finding from 1 review
Overall survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in event‐free survival compared with standard induction therapies (low certainty).
1 finding from 1 review
Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... · patients with high‐risk neuroblastoma
1 finding from 1 review
Recurrent and persistent bleeding overall rates with or without second‐look endoscopy Rebleeding (persistent or recurrent bleeding) · patients with high‐risk bleeding ulcers
Epinephrine probably leads to lower recurrent and persistent bleeding overall rates with or without… compared with epinephrine and any second endoscopic method (moderate certainty).
1 finding from 1 review